Fibrofolliculomas are small, smooth, skin-colored bumps that grow around a hair follicle. They are benign (not cancer). Each bump is usually 2–4 mm across, dome-shaped, and the surface feels smooth or slightly rubbery. They most often appear on the face (nose, cheeks, forehead), ears, neck, and upper trunk. Under the microscope, fibrofolliculomas show thin cords and strands of follicle-like cells spreading out from the upper part of a hair follicle into a fibrous (collagen-rich) stroma around it. This combination of follicle epithelium and surrounding fibrous tissue is the key feature that defines the lesion. DermNet®+2DermNet®+2

Fibrofolliculomas are small, dome-shaped, skin-colored bumps that arise from the hair follicle. They are benign (non-cancerous) hamartomas—meaning an overgrowth of normal skin structures in the wrong proportion. Many people develop multiple bumps on the face, neck, and ears, and the number can increase with age. Fibrofolliculomas commonly occur as part of Birt-Hogg-Dubé syndrome (BHD), a hereditary condition caused by changes (pathogenic variants) in the FLCN gene, although solitary sporadic lesions can also occur. Diagnosis is mainly clinical and can be confirmed with a small skin biopsy that shows fibrous tissue around distorted hair follicles. The bumps are harmless but can be cosmetically bothersome; they may recur after removal. NCBI+1

The FLCN gene encodes a protein called folliculin, which works with partner proteins (FNIP1/2) and interfaces with nutrient-sensing pathways (notably mTORC1/Rag GTPases) that influence cell growth. In BHD, faulty folliculin signaling is thought to drive formation of fibrofolliculomas (skin lesions), lung cysts/pneumothorax, and kidney tumors. Although details are still being researched, loss of normal tumor-suppressor function of FLCN and dysregulation of mTORC1 signaling appear central. Frontiers+2PMC+2

A single fibrofolliculoma can happen by itself (sporadic). However, when there are many such bumps—often dozens or more—they are commonly part of an inherited condition called Birt–Hogg–Dubé (BHD) syndrome. BHD is caused by a change (pathogenic variant) in the FLCN gene, which encodes the protein folliculin. People with BHD have a higher chance of kidney tumors and lung cysts with spontaneous pneumothorax, so recognizing the skin bumps can be lifesaving because it leads to proper screening. NCBI+2NCBI+2

---

Other names

• Trichodiscoma: Many experts consider trichodiscoma a close relative or a fibrous-predominant variant of fibrofolliculoma; both occur in BHD and may represent points on a spectrum. DermNet®

• Perifollicular fibroma: Sometimes used in older literature for similar perifollicular fibrous lesions; usage now tends to separate it from classic fibrofolliculoma based on histology. DermNet®

• Fibrofollicular hamartoma: Highlights that this is a hamartomatous (overgrowth of normal elements) lesion of the hair follicle. PMC

• When multiple: “Multiple fibrofolliculomas” or “BHD-associated fibrofolliculomas.” NCBI

---

Types

1. Sporadic (solitary) fibrofolliculoma
   A single lesion in someone without other signs of BHD. It is benign and usually removed for diagnosis or cosmetic reasons. Histology still shows the follicular epithelial cords in a fibrous stroma. PMC

2. Syndromic (BHD-associated) multiple fibrofolliculomas
   Dozens to hundreds of lesions that appear in early to mid-adulthood. These are a major diagnostic skin sign of BHD. Recognizing them should prompt FLCN genetic testing and kidney/lung surveillance. PMC+1

3. Histologic spectrum lesions (fibrofolliculoma ↔ trichodiscoma)
   Some lesions show more epithelial strands (fibrofolliculoma-predominant), while others show more fibrous stroma (trichodiscoma-predominant). They are closely related and can coexist in the same person. DermNet®

4. Variant morphologies (rare)
   Comedonal or cystic fibrofolliculomas have been described in BHD, where follicular openings or cyst-like changes are prominent, but the basic diagnostic pattern is preserved. PMC

---

Causes

Key point: The single best-proven cause of multiple fibrofolliculomas is Birt–Hogg–Dubé syndrome due to a pathogenic variant in FLCN. Many of the factors below describe the genetic and cellular mechanisms that flow from FLCN loss. For solitary lesions, the exact cause is usually unknown (sporadic). I’ll be explicit about the strength of evidence.

1. Germline FLCN pathogenic variants (BHD) – Strong evidence. This autosomal-dominant change drives the tendency to form many fibrofolliculomas. NCBI+1

2. “Second hit” in FLCN within skin cells – In tumors/hamartomas, a second somatic change can inactivate the remaining FLCN copy, pushing local follicle cells to overgrow. PMC

3. mTORC1 signaling imbalance from FLCN loss – FLCN regulates the mTORC1 nutrient-sensing pathway via Rag GTPases; its loss disturbs growth signals in follicle cells. ScienceDirect+2PMC+2

4. AMPK pathway changes – FLCN interacts with AMPK; loss can lead to constitutive AMPK activation and altered cell metabolism. PubMed+1

5. TFEB/TFE3 activation – Without normal FLCN function, mTORC1 fails to restrain TFEB/TFE3, shifting lysosome/autophagy programs and promoting abnormal growth. PMC+1

6. Altered lysosomal nutrient sensing – FLCN acts as a GAP for RagC/D to recruit mTORC1 to lysosomes; disruption perturbs growth control. ScienceDirect+1

7. Broader signaling crosstalk (WNT, HIF, autophagy) – Research suggests FLCN influences several networks that affect how follicle cells grow and remodel. (Mechanistic studies; human causal strength varies.) Nature

8. Autosomal-dominant inheritance pattern – A parent with BHD can pass on the variant; penetrance for skin bumps is high. NCBI

9. Age-related expression in BHD – Lesions usually appear in adulthood (third to fifth decade), suggesting time-dependent accumulation of somatic events. NCBI

10. Sporadic (idiopathic) solitary lesions – Cause unknown; not linked to germline FLCN in most cases; considered hamartomatous. PMC

11. Comedonal or cystic follicular changes – In rare BHD variants, follicular occlusion may modify lesion shape but is not a root cause. (Adjunct observation.) PMC

12. Modifier genes/environment in BHD – People with the same FLCN variant can show different numbers of lesions, implying modifiers; specifics remain under study. Cancer.gov

13. Skin site susceptibility (face/neck) – Areas rich in vellus/terminal follicles may favor lesion growth in BHD; mechanism likely anatomic rather than external. DermNet®

14. No proven link to sun exposure – UV may affect many skin conditions, but a direct causal role in fibrofolliculomas is unproven. (Negative statement based on guideline/dermatology sources.) DermNet®+1

15. No proven link to friction/metabolic syndrome – Unlike skin tags, fibrofolliculomas are not clearly caused by friction or insulin resistance. (Differential clarification.) DermNet®

16. Hair-follicle stromal remodeling – The hallmark fibrous stroma suggests dysregulated fibroblast-epithelium signaling around follicles in FLCN loss. (Mechanistic inference from pathology.) DermNet®

17. Lysosome–mitochondria metabolic shifts – FLCN/AMPK/PGC1α axes can alter cellular energy handling, which may support hamartoma growth. (Cell biology evidence.) PubMed

18. Stem/progenitor cell effects – FLCN influences cell fate programs in experimental systems; relevance to human lesions is plausible but not fully defined. Nature

19. Context-dependent signaling – FLCN functions differ by tissue and cell type, helping explain why skin, lung, and kidney are affected in BHD. Nature

20. Family history as a risk clue – Multiple first-degree relatives with similar facial bumps or BHD features raises the likelihood of inheriting FLCN variants. NCBI

Symptoms and sign

1. Small, smooth, skin-colored papules on face, ears, neck, upper trunk; usually 2–4 mm, dome-shaped. These are the classic bumps. DermNet®

2. Multiple lesions developing over years, sometimes dozens to hundreds in BHD. DermNet®

3. Onset in adulthood (often 20s–40s) for BHD-related lesions. NCBI

4. Cosmetic concern (appearance). The bumps are benign but noticeable. DermNet®

5. Usually no pain or itch. Most lesions are asymptomatic unless irritated. DermNet®

6. Distribution on hair-bearing skin, reflecting origin from hair follicles. DermNet®

7. Coexisting trichodiscomas or skin tags in the same person, especially in BHD. DermNet®

8. Oral mucosal papules (occasionally) reported in BHD. DermNet®

9. Stable or slowly increasing number over time. Once present, lesions are persistent. DermNet®

10. Shaving trauma/bleeding if raised lesions catch on razors—practical issue rather than disease activity. (Clinical observation consistent with raised papules.) DermNet®

11. Family history of similar facial bumps and/or BHD features (kidney tumors, lung cysts). NCBI

12. No systemic symptoms from the skin bumps themselves; any systemic risk comes from the underlying BHD syndrome (kidney/lung). NCBI+1

13. Color: white to flesh-colored. They usually match surrounding skin. DermNet®

14. Surface: smooth, sometimes with a central pore in comedonal variants. PMC

15. Lesion firmness: soft to rubbery on palpation due to fibrous stroma. (Correlates with histology.) DermNet®

---

Diagnostic tests

Note: Diagnosis of a single lesion is often made by skin biopsy. Diagnosis of multiple lesions should trigger evaluation for BHD (including FLCN testing and kidney/lung imaging per guidelines). There is no role for electrodiagnostic tests in fibrofolliculomas.

A) Physical examination

1. Full-skin visual inspection
   The clinician looks for small, smooth, dome-shaped, skin-colored papules on typical sites (face, ears, neck, upper trunk). Number and symmetry matter. This first step raises suspicion for fibrofolliculomas, especially when there are many. DermNet®

2. Pattern and distribution mapping
   Clustering on the central face and behind/around the ears supports the diagnosis and helps separate from acne, milia, or syringomas. DermNet®

3. Syndromic screening at the bedside
   The clinician asks about family history of similar bumps, kidney tumors, lung cysts, and spontaneous pneumothorax to screen for BHD. NCBI+1

4. Differential diagnosis check
   Angiofibromas (tuberous sclerosis), syringomas, milia, trichoepitheliomas, skin tags, and sebaceous hyperplasia can mimic fibrofolliculomas. Clues like telangiectasia, umbilication, or pearly translucency can point elsewhere. Histology resolves uncertainty. DermNet®

B) “Manual” bedside tools

5. Dermoscopy
   A handheld scope can show whitish/skin-colored structureless areas with fine vessels and sometimes a central follicular opening; not specific but supports a follicular process and guides where to biopsy. (Adjunctive description consistent with follicular lesions.) DermNet®

6. Palpation (consistency test)
   Gentle rolling between fingers reveals a soft to rubbery papule, consistent with fibrous stroma. This helps separate it from calcified or cystic nodules. (Clinical–pathologic correlation.) DermNet®

7. Diascopy (glass slide pressure)
   Blanching may help distinguish vascular lesions (angiomas) from non-vascular papules like fibrofolliculomas, which do not fully blanch. (General dermatologic principle.) DermNet®

8. Site photography for lesion count
   Standardized photos help document number and progression over time, which matters for BHD surveillance and patient counseling. (Guideline-consistent approach to dermatologic monitoring.) PubMed

C) Laboratory & pathological tests

9. Shave biopsy
   A shallow biopsy removes the top of the papule. Histology then shows anastomosing epithelial strands from the infundibulum in a perifollicular fibrous stroma, which is diagnostic. DermNet®

10. Punch biopsy
    A cylindrical sample that includes the full thickness of the lesion and follicular unit. Useful when architecture is needed to separate fibrofolliculoma from trichodiscoma or other appendage tumors. DermNet®

11. Routine histopathology (H&E)
    The key features are follicular epithelial cords, sometimes surrounding a dilated follicular infundibulum, extending into a fibrous stroma with perifollicular mucin. This pattern defines fibrofolliculoma. DermNet®

12. FLCN germline genetic testing (blood/saliva)
    Recommended when multiple lesions suggest BHD or there is family history. Identifying a pathogenic FLCN variant confirms the syndrome and prompts kidney/lung surveillance. NCBI+1

13. Targeted multigene panel (if appropriate)
    In a hereditary renal cancer or pneumothorax workup, panels that include FLCN can detect BHD when skin signs are subtle. Cancer.gov

14. Pathology correlation across lesions
    If some bumps look different, sampling more than one can show the fibrofolliculoma↔trichodiscoma spectrum, reinforcing the diagnosis in BHD. DermNet®

D) Electrodiagnostic tests

15. Electrodiagnostic studies (e.g., nerve conduction, EMG)
    Not used for fibrofolliculomas. These lesions are cutaneous and benign; there is no role for nerve or muscle electrical testing in diagnosis. (Explicit exclusion based on disease biology and guidelines.) PubMed

To keep the total count at 20 tests, we include zero in this category and expand imaging and pathology where clinically relevant.

E) Imaging tests

16. High-resolution CT (HRCT) of the chest
    Detects lung cysts typical of BHD and helps risk-stratify for spontaneous pneumothorax. This is part of syndromic assessment when multiple fibrofolliculomas are present. NCBI

17. Renal MRI (preferred for surveillance)
    Non-ionizing imaging to look for renal cell carcinoma (RCC) associated with BHD. Guidelines recommend lifelong renal surveillance in adults diagnosed with BHD. PubMed+1

18. Renal CT (contrast-enhanced, if MRI unavailable)
    Alternative to MRI for detecting small, multifocal, or bilateral tumors that are typical in BHD. PMC+1

19. Renal ultrasound (screening adjunct)
    May be used between more sensitive studies, but small BHD-related tumors can be missed; many centers favor MRI/CT as primary tools. PubMed

20. Clinical photography + serial skin exams
    Imaging in the broad sense—standardized photos and regular dermatology visits—to document lesion burden over time and to support patient counseling in BHD. PubMed

Non-pharmacological treatments (therapies & others)

1. Watchful waiting & education (first step) – Description: Because fibrofolliculomas are benign, doing nothing is safe if the bumps do not bother you. Your clinician explains the diagnosis, shows photos, and discusses options and expectations (including recurrence). Purpose: reduce anxiety and support informed choice. Mechanism: no physical intervention—relies on understanding the benign nature and monitoring for change. Evidence from BHD resources shows lesions are cosmetic, but the syndrome has lung/kidney risks that need separate surveillance. NCBI

2. Sun protection & gentle skincare – Description: Daily broad-spectrum sunscreen, non-abrasive cleansers, and avoiding harsh scrubs can lower irritation and make bumps less noticeable. Purpose: protect skin barrier and reduce inflammation that can accentuate texture. Mechanism: UV protection and barrier support may limit post-procedure hyperpigmentation and improve cosmetic outcomes after removals. Guidance is general to dermatology care; fibrofolliculomas themselves are not UV-driven. ScienceDirect

3. Camouflage cosmetics – Description: Tinted moisturizers or medical-grade concealers can mask color and shadowing of bumps, improving confidence for events without medical risk. Purpose: cosmetic blending when procedures are not desired. Mechanism: optical blurring and pigment coverage of surface irregularities. ScienceDirect

4. Electrodesiccation / hyfrecation – Description: Office-based pinpoint electrical cautery to flatten individual papules under local anesthesia. Purpose: quick reduction of the most visible bumps. Mechanism: controlled thermal destruction of superficial lesion tissue; often combined with gentle curettage. Recurrence is possible as follicles regenerate. Medscape

5. Radiofrequency ablation – Description: Similar to electrodesiccation but using radiofrequency energy to vaporize the papule with precise control. Purpose: treat multiple lesions in one session. Mechanism: thermal ablation of protruding follicular tissue with hemostasis; healing by secondary intention. Medscape

6. Shave removal – Description: A curved blade shaves the dome of the bump after numbing. Purpose: immediate flattening and a specimen for confirmation. Mechanism: tangential excision at the skin surface; may be followed by gentle cautery. Recurrence is common due to residual follicular units. ScienceDirect

7. Punch excision – Description: A circular blade removes the full core when a deeper sample is needed. Purpose: definite diagnosis for atypical or solitary lesions. Mechanism: complete lesion extraction with stitches; best for single or suspicious papules. ScienceDirect

8. CO₂ laser (ablative resurfacing) – Description: Fractionated or full-field carbon dioxide laser precisely removes thin skin layers to flatten many papules in one or more sessions. Purpose: efficient cosmetic smoothing for widespread lesions. Mechanism: water-targeting laser ablates columns or sheets of tissue; collagen remodeling smooths texture. Recent case reports show good short-term outcomes; recurrence can occur over time. jaadcasereports.org+1

9. Er:YAG laser – Description: Erbium:YAG ablation has a higher water absorption and shallower thermal injury than CO₂, sometimes preferred for precise, lighter resurfacing. Purpose: treat clusters on the face with faster healing. Mechanism: photoablation of superficial tissue; less heat spread than CO₂. Published experience is limited but supportive. JAAD+1

10. Combined CO₂ + pulsed dye laser (PDL) – Description: Some centers combine ablative CO₂ (to debulk) with PDL (to reduce vascular redness) for better cosmetic blending. Purpose: improve texture and color in the same plan. Mechanism: CO₂ ablates; PDL targets hemoglobin to reduce erythema. Emerging case data suggest benefit. PAGEPress+1

11. Dermabrasion / microdermabrasion (adjunct) – Description: Mechanical planing can modestly smooth surfaces but is less targeted than lasers and may be best after initial debulking. Purpose: polish residual roughness. Mechanism: controlled mechanical removal of superficial layers. Evidence is older and limited. Medscape

12. Scar-care protocol after removals – Description: Gentle cleansing, petrolatum, silicone gel/sheets, and sun avoidance during healing. Purpose: reduce pigment change and scarring after procedures. Mechanism: moist wound healing and silicone occlusion to modulate collagen. ScienceDirect

13. Session staging & mapping – Description: Treat in prioritized zones (e.g., nose/cheeks first) with interval follow-ups. Purpose: control downtime and check response. Mechanism: incremental resurfacing and patient-reported outcome tracking. Medscape

14. Psychosocial support – Description: Visible facial bumps can affect self-image. Brief counseling, peer groups, or referral if distress is high. Purpose: mental health and adherence support. Mechanism: coping strategies improve quality of life. NCBI

15. Smoking cessation (for BHD lungs) – Description: While it doesn’t shrink bumps, quitting smoking lowers pneumothorax risk and supports surgery/laser healing. Purpose: reduce lung events in BHD. Mechanism: less alveolar stress and better tissue oxygenation. ERS Publications

16. Renal & chest surveillance (BHD care) – Description: Periodic kidney MRI and chest assessment don’t treat bumps, but they treat the whole person with BHD. Purpose: early detection of renal tumors and lung issues. Mechanism: guideline-based imaging schedules. NCBI

17. Procedure anesthesia optimization – Description: Topical anesthetic + small local injections minimize pain so more lesions can be treated per session. Purpose: comfort and efficiency. Mechanism: lidocaine blocks nerve signaling. Medscape

18. Wound-care education – Description: Clear instructions (cleanse, ointment, sun avoidance) reduce complications and pigment changes. Purpose: faster, better cosmetic healing. Mechanism: barrier restoration. ScienceDirect

19. Recurrence planning – Description: Set expectations that follicles can regrow and touch-ups are normal. Purpose: reduce frustration and support adherence. Mechanism: scheduled maintenance. Medscape

20. Clinical photography follow-up – Description: Before/after photos help guide if and when to repeat procedures. Purpose: objective progress tracking. Mechanism: consistent images as outcome measures. Medscape

---

Drug treatments

Important reality check: There are no FDA-approved medicines specifically for fibrofolliculomas. Drugs below are off-label or used for related skin conditions; evidence ranges from case reports to small studies, and benefit is modest or inconsistent. Label citations come from accessdata.fda.gov to document each drug’s class, dosing, and safety—not an approval for fibrofolliculomas.

1. Topical sirolimus (rapamycin) – OFF-LABEL (mTOR inhibitor). Description (~150 wds): Sirolimus blocks mTOR signaling, a pathway linked to FLCN biology. It helps certain mTOR-driven skin lesions (e.g., tuberous sclerosis angiofibromas). In fibrofolliculomas, the best trial—a randomized split-face study—found no meaningful cosmetic benefit over placebo after 6 months, though some individuals reported slight improvement. Purpose: attempt pathway-targeted smoothing. Mechanism: mTORC1 inhibition may reduce abnormal growth. Side effects: irritation, acneiform rash. (Use only with specialist guidance.) PMC+1
   Label reference for drug class/safety: RAPAMUNE® (sirolimus). FDA Access Data

2. Oral sirolimus – OFF-LABEL. Description: Systemic mTOR inhibition is not recommended solely for cosmetic fibrofolliculomas given immunosuppression risks (infection, lipids, mouth ulcers), and no proven benefit for these lesions. Purpose: generally not used for this indication. Mechanism/side effects per label. FDA Access Data

3. Everolimus (AFINITOR®) – OFF-LABEL. Description: Another mTOR inhibitor approved for cancers and TSC-related tumors. For fibrofolliculomas, there is no high-quality evidence of cosmetic benefit, and systemic risks outweigh unclear gains. Purpose: typically not used for fibrofolliculomas. Mechanism/side effects per label. FDA Access Data

4. Imiquimod 5% cream – OFF-LABEL (immune response modifier). Description: Approved for actinic keratoses, superficial basal cell carcinoma, and genital warts, imiquimod up-regulates local immune signaling. Case reports show it can shrink other follicular tumors, but data for fibrofolliculomas are not robust; irritation and redness are common, and lesions may recur. Purpose: test small areas when procedures are not desired. Mechanism: TLR7-mediated immune activation and antitumor effects. Side effects: inflammation, erosion, pigment change. FDA Access Data+1
   Label reference: ALDARA® (imiquimod) 5% label. Office of Dietary Supplements

5. 5-Fluorouracil (EFUDEX®) cream – OFF-LABEL. Description: A topical chemotherapy for actinic keratoses and superficial BCC. It damages rapidly dividing cells. It is not proven for fibrofolliculomas; occasionally tried for field textural change but can cause brisk inflammation. Purpose: rarely considered; procedures work better. Mechanism: thymidylate synthase inhibition → DNA synthesis block. Side effects: marked erythema, crusting. FDA Access Data

6. Topical tretinoin (RETIN-A® / Retin-A Micro®) – OFF-LABEL. Description: A vitamin A derivative that normalizes keratinization and smooths fine surface irregularities. It does not remove fibrofolliculomas but may soften look/feel slightly over months; irritation and photosensitivity are common. Purpose: mild cosmetic adjunct. Mechanism: RAR-mediated gene expression, faster epidermal turnover. Side effects: dryness, peeling, sun sensitivity. FDA Access Data+1

7. Topical tazarotene (TAZORAC®) – OFF-LABEL. Description: A potent topical retinoid (prodrug) that can refine texture in acne/psoriasis. For fibrofolliculomas, benefit is theoretical (keratin normalization); irritation risk is higher than adapalene/tretinoin. Purpose: limited role as adjunct. Mechanism: RARβ/γ-selective modulation. Side effects: irritation, teratogenicity warnings. FDA Access Data

8. Topical adapalene (DIFFERIN®) – OFF-LABEL. Description: A gentler retinoid sometimes used for texture. Expect subtle changes at best; use sunscreen and go slow. Purpose: minor adjunct. Mechanism: retinoid receptor modulation affecting differentiation. Side effects: irritation, dryness. FDA Access Data

9. Oral isotretinoin – OFF-LABEL. Description: Systemic retinoid for severe acne. Some reports mention variable softening of multiple follicular papules, but regrowth is typical and risks (teratogenicity, lipids, mood changes) are significant; not a routine option for fibrofolliculomas. Purpose: generally not recommended for cosmetic hamartomas. Mechanism: sebaceous suppression, keratinization reset. Side effects per label. FDA Access Data

10. Acitretin (SORIATANE®) – OFF-LABEL. Description: Oral retinoid for psoriasis. Might modestly affect follicular hyperkeratosis but not proven for fibrofolliculomas; adverse effect profile is substantial and long pregnancy avoidance is required post-treatment. Purpose: rarely appropriate. Mechanism/side effects per label. FDA Access Data

11. Tacrolimus ointment (PROTOPIC®) – OFF-LABEL. Description: A calcineurin inhibitor for atopic dermatitis. Sometimes tried to reduce irritation or post-procedure inflammation but does not remove fibrofolliculomas. Purpose: barrier-friendly anti-inflammatory adjunct. Mechanism: T-cell activation blockade. Side effects: burning, theoretical malignancy warnings. FDA Access Data

12. Pimecrolimus cream (ELIDEL®) – OFF-LABEL. Description: Similar to tacrolimus, may calm irritated skin after procedures; not a lesion remover. Purpose: comfort. Mechanism: calcineurin inhibition. Side effects as labeled. FDA Access Data

13. Eflornithine cream (VANIQA®) – OFF-LABEL. Description: Approved to slow unwanted facial hair in women by inhibiting ornithine decarboxylase. It doesn’t shrink fibrofolliculomas but can reduce “hair shadow” through bumps. Note: product availability has varied. Purpose: cosmetic adjunct for facial hair. Mechanism/label details cited. FDA Access Data

14. Post-procedure antibiotic ointments (short course). Description: Petrolatum is usually enough; brief mupirocin may be used when infection risk is higher. Purpose: safe healing. Mechanism: topical antibacterial coverage. Use sparingly and short-term. (General wound-care practice; no fibrofolliculoma-specific approval.) ScienceDirect

15. Topical corticosteroids (very short term). Description: Low- to mid-potency steroids calm post-laser inflammation for a day or two. Purpose: comfort; not a treatment for the bump itself. Mechanism: anti-inflammatory gene regulation. Use conservatively on the face. Medscape

16. Hydroquinone (peri-procedural hyperpigmentation control) – OFF-LABEL. Description: In pigment-prone skin, short pre/post-laser use may reduce darkening; not for lesion removal. Purpose: color control. Mechanism: tyrosinase inhibition. Risks: irritation/ochronosis with misuse—specialist guidance needed. Medscape

17. Topical anesthetics (lidocaine/prilocaine). Description: Used before procedures so more bumps can be treated. Purpose: pain control. Mechanism: sodium-channel blockade. Not a lesion therapy. Medscape

18. Emollients/petrolatum. Description: Support barrier and healing after removals; improve skin feel. Purpose: comfort and better scars. Mechanism: occlusion and hydration. ScienceDirect

19. Silicone gel/sheets. Description: Help flatten and lighten post-procedure scars over weeks. Purpose: reduce scarring appearance. Mechanism: hydration/occlusion signaling to collagen. ScienceDirect

20. Antiseptic cleansers (short course). Description: Gentle antiseptics (e.g., chlorhexidine wash) may be used around procedures to lower infection risk. Purpose: cleaner field. Mechanism: reduce skin bioburden. Medscape

---

Dietary molecular supplements

1. Vitamin C – Supports collagen formation and wound healing after procedures; excess doses can upset the stomach. Typical diet suffices; supplements vary by person. Mechanism: cofactor for collagen hydroxylation and antioxidant action. Office of Dietary Supplements

2. Zinc – Important for epithelial repair; deficiency impairs healing. Do not exceed upper limits unless medically indicated. Mechanism: enzyme cofactor in DNA synthesis and repair. PMC

3. Vitamin A – Essential for epithelial differentiation; avoid high doses (toxicity) and strictly avoid with oral retinoids. Mechanism: retinoid pathway support. Office of Dietary Supplements

4. Vitamin D – Supports immune function and general skin health when deficient; supplement only if low per tests. Mechanism: nuclear receptor signaling affecting immunity. Office of Dietary Supplements

5. Omega-3 fatty acids – May help general inflammation balance and support skin barrier. Mechanism: eicosanoid modulation. APIM

6. Protein/essential amino acids – Adequate protein aids wound healing after laser/shave. Mechanism: substrate for collagen and tissue repair. (General nutrition guidance.) Office of Dietary Supplements

7. Copper (trace) – Cofactor for lysyl oxidase in collagen cross-linking; deficiency is rare; avoid excess. Mechanism: matrix cross-linking support. Office of Dietary Supplements

8. Selenium (trace) – Antioxidant enzyme cofactor; do not exceed upper limits. Mechanism: glutathione peroxidase support. Office of Dietary Supplements

9. Green-tea polyphenols (topical/oral) – Antioxidant properties; may modestly calm post-procedure redness; evidence is general to skin care. Mechanism: ROS scavenging. APIM

10. Niacinamide – Often used topically; oral form in specific contexts supports barrier and pigmentation balance. Mechanism: NAD+ pathway support and anti-inflammatory effects. (General dermatology evidence.) Office of Dietary Supplements

---

Immunity-booster / regenerative / stem-cell” drugs

Clear safety note: There are no approved “immunity-booster” or regenerative/stem-cell drugs for fibrofolliculomas. The items below explain what is discussed and why routine use is not recommended.

1. Systemic mTOR inhibitors (sirolimus/everolimus) – Target a pathway tied to FLCN biology but carry significant immunosuppression risk and lack proven cosmetic benefit for fibrofolliculomas. Reserved for other labeled indications; not advised for cosmetic bumps. FDA Access Data+2FDA Access Data+2

2. Topical sirolimus – Mechanistically attractive, but the best trial showed no meaningful improvement over placebo. Can irritate skin; consider only in research or with specialist counseling. PMC

3. Topical growth-factor cosmeceuticals – Marketed for rejuvenation; not drugs and not proven to remove fibrofolliculomas. Discuss expectations carefully. ScienceDirect

4. Platelet-rich plasma (PRP) – A regenerative dermatology technique for other conditions; no evidence it shrinks fibrofolliculomas. Not recommended for this purpose. ScienceDirect

5. Stem-cell products – Avoid unapproved stem-cell therapies; the FDA warns many are illegal or unsafe outside clinical trials. No role for fibrofolliculomas.

6. Imiquimod – An immune response modifier; may inflame/smooth some lesions in case reports of other follicular tumors, but evidence for fibrofolliculomas is weak and recurrence common. PMC

---

Surgeries (procedures)

Shave excision – Quick office removal of the visible dome after numbing; good for single standout bumps or for diagnosis. Done to flatten and to get tissue for the lab. Recurrence can happen because the hair unit remains. ScienceDirect

Punch excision – Circular full-thickness removal with sutures; best for solitary lesions or when pathology clarity is needed. Done for complete removal and histology. ScienceDirect

Electrosurgery/curettage – Heat and gentle scraping to debulk many lesions in one visit. Done to rapidly smooth the most visible areas; recurrence is expected over time. Medscape

CO₂ laser resurfacing – Fractionated or non-fractionated ablation to treat many papules efficiently; often needs repeat sessions in future years. Done for broader cosmetic blending. jaadcasereports.org

Er:YAG laser – Alternative ablative method with precise superficial ablation and fast healing; also may require staged sessions. Done when fine control is desired. JAAD

---

Preventions

1. You cannot fully “prevent” fibrofolliculomas in BHD, but early recognition helps plan safe care. NCBI

2. Family counseling/genetic testing when appropriate can clarify risk for relatives. NCBI

3. Sun protection reduces post-procedure darkening and irritation (cosmetic benefit). ScienceDirect

4. Gentle shaving/grooming lowers trauma to raised papules. ScienceDirect

5. Don’t pick/squeeze lesions—prevents bleeding and scarring. ScienceDirect

6. Plan maintenance (touch-ups) since recurrence is common. Medscape

7. Stop smoking (BHD lungs) to lower pneumothorax risk and support healing. ERS Publications

8. Keep BHD surveillance (kidney MRI schedule) even if the skin looks stable. NCBI

9. Choose experienced centers for lasers to minimize scarring and pigment change. jaadcasereports.org

10. Photographs/records help time repeat treatments before lesions become more numerous. Medscape

---

When to see doctors

See a dermatologist if you notice many new facial bumps, especially with a family history of collapsed lung (pneumothorax) or kidney tumors—this triad points to possible BHD. Seek care sooner if bumps change color rapidly, ulcerate, or bleed, because those are not typical for benign fibrofolliculomas and need a biopsy. If BHD is suspected or confirmed, you should also see clinicians familiar with kidney imaging and lung cyst care for surveillance. NCBI+1

---

Foods to eat & to avoid

What to eat:

1. Lean proteins (fish, eggs, legumes) to support healing after procedures. Office of Dietary Supplements
2. Vitamin-C–rich produce (citrus, berries, peppers) for collagen support. Office of Dietary Supplements
3. Zinc sources (beans, nuts, seeds) for repair. PMC
4. Colorful vegetables (antioxidants). Office of Dietary Supplements
5. Whole grains for steady energy during healing. Office of Dietary Supplements
6. Omega-3s (salmon, flax, walnuts) for inflammation balance. APIM
7. Low-fat dairy or fortified alternatives (vitamin D/protein) if tolerated. Office of Dietary Supplements
8. Hydration (water/herbal teas). Office of Dietary Supplements
9. Iron sources if you’re low (leafy greens/legumes) to support recovery as advised. Office of Dietary Supplements
10. Niacinamide-rich foods (poultry, peanuts) as part of balanced diet. Office of Dietary Supplements

What to limit/avoid:

1. Excess alcohol (impairs healing). Office of Dietary Supplements
2. High-sugar ultra-processed foods (worsen inflammation). Office of Dietary Supplements
3. Very spicy/acidic foods just before procedures if they trigger flushing. Office of Dietary Supplements
4. Megadose supplements beyond safe upper limits without testing (e.g., zinc, selenium, vitamin A). PMC+1
5. Smoking/nicotine (healing problems). ERS Publications
6. New herbal products right before laser/surgery (bleeding/irritation risk). Medscape
7. Tanning/UV exposure (pigment change post-procedure). FDA Access Data
8. Harsh scrubs/peels around treatment time (irritation). FDA Access Data
9. Unverified “stem-cell” supplements (safety/false claims).
10. Self-mixing retinoids/peels before a procedure (burn risk). FDA Access Data

---

FAQs

1) Are fibrofolliculomas dangerous?
No. They are benign bumps. The concern is mainly cosmetic—but if you have many, doctors think about BHD, which carries lung and kidney risks that need screening. NCBI

2) Do creams remove them?
Not reliably. Off-label creams (retinoids, imiquimod, rapamycin) show inconsistent or minimal benefit; procedures work better. PMC+1

3) Which procedure lasts the longest?
No method is truly permanent because hair units can regrow. CO₂ or Er:YAG laser often smooth many bumps efficiently, but touch-ups are common. jaadcasereports.org+1

4) Will they turn into cancer?
Fibrofolliculomas themselves are benign. In BHD, the kidney risk is separate and needs its own imaging plan. NCBI

5) I have one solitary bump—do I need genetic testing?
Usually not unless you also have family/systemic clues (pneumothorax, kidney tumors). Your dermatologist can guide. NCBI

6) Can diet remove the bumps?
No diet removes them. Nutritious eating supports healing after procedures. Office of Dietary Supplements

7) Do I need to avoid exercise?
Not for the bumps. If BHD is diagnosed, discuss diving or unpressurized air travel due to pneumothorax risk. NCBI

8) Are lasers safe on darker skin?
They can be, with experienced hands and careful settings; pigment changes are the main risk. Pre/post-care reduces this. Medscape

9) Is topical rapamycin worth trying?
The best trial showed no significant benefit; some individuals felt mild improvement. Discuss expectations and irritation risks with your dermatologist. PMC

10) Can I shave over them?
Yes, with care. Use sharp blades and gentle technique to avoid nicking raised papules. ScienceDirect

11) How often should BHD kidneys be checked?
Kidney MRI at intervals per expert guidance (often every 1–2 years), individualized by your genetics team. NCBI

12) Are stem-cell treatments available?
No approved stem-cell products for these bumps; the FDA warns about unapproved regenerative therapies.

13) Do bumps stop appearing?
They may slowly accumulate with age in BHD; maintenance touch-ups are normal. NCBI

14) Will pregnancy or hormones change them?
Data are limited; lesions may change with time, but clear hormonal effects are not established. Ask your dermatologist for personalized advice. ScienceDirect

15) Can fibrofolliculomas appear outside the face?
Yes—neck and ears are common; sometimes upper trunk. Distribution plus family/systemic clues guide testing. NCBI

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 27, 2025.